Business / Finance

RSS

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2015 Annual General Meeting of Shareholders held on Tuesday, August 11, 2015 in Beijing, PRC.

11 Aug 2015

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

AXT is proud to announce that they have just signed an exclusive distributorship agreement with US-based Endra Life Sciences. Endra are a developer of photoacoustic (PA) technology for bio-medical imaging and have commercialised their breakthrough technology. This new deal further bolsters AXT’s life science and preclinical imaging portfolios with another unique technology.

From MR Solutions 11 Aug 2015

VolitionRx reports net loss of $1.9 million for second quarter 2015

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the second quarter ended June 30, 2015.

11 Aug 2015

Deerfield provides $20 million financing to Editas Medicine

Deerfield Management Company, L.P.'s venture capital fund, Deerfield Healthcare Innovations Fund, L.P., today announced its first therapeutics-based investment by participating, along with Deerfield Private Design Fund III, in providing financing to Editas Medicine. In total, Deerfield invested $20 million in this early-stage institutional financing.

10 Aug 2015

BioScrip revenue increases 6.2% to $262.4 million in second quarter 2015

BioScrip, Inc. today announced 2015 second quarter financial results. Second quarter revenue from continuing operations was $262.4 million and the net loss from continuing operations was $243.2 million, or $3.60 loss per diluted share, which includes a $238.0 million pre-tax goodwill impairment charge resulting from a decline in the Company's common stock price and related market capitalization, as well as an $8.6 million incremental pre-tax bad debt charge predominately attributable to aged accounts receivable balances over 365 days old.

10 Aug 2015

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Impax Laboratories, Inc. today announced that it has sold its U.S. rights to the Daraprim brand to Turing Pharmaceuticals AG for approximately $55 million.

10 Aug 2015

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Intrexon Corporation, a leader in synthetic biology, and Synthetic Biologics, Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, today announced an Exclusive Channel Collaboration (ECC) to pursue the development and commercialization of novel biotherapeutics for the treatment of patients with phenylketonuria (PKU), a serious and debilitating metabolic disorder.

10 Aug 2015

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals AG today announced that it has acquired the exclusive rights to market Daraprim (pyrimethamine) in the U.S. from Impax Laboratories, Inc. The acquisition by Turing is part of a strategic effort focused on treatments for toxoplasmosis and other serious infectious diseases. The company also announced plans to invest in the development of new drug candidates for toxoplasmosis.

10 Aug 2015

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Sorrento Therapeutics, Inc. announced today that its wholly-owned subsidiary, TNK Therapeutics, Inc., has acquired multiple preclinical and clinical stage chimeric antigen receptor (CAR)-T immunotherapy programs as well as underlying CAR-T technology through the acquisition of two privately-held biotechnology companies.

10 Aug 2015

Turing Pharmaceuticals completes $90 million Series A financing

Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on discovering and developing treatments for serious and life-threatening diseases, today announced the completion of its Series A financing. The $90 million round was led by Martin Shkreli, Founder & Chief Executive Officer.

10 Aug 2015

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

Mallinckrodt plc, a leading specialty biopharmaceutical company, and The Gores Group, a global investment firm, announced today that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at approximately $1.325 billion.

10 Aug 2015

GenVec reports net loss of $1.9 million for second quarter 2015

GenVec, Inc. today reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, GenVec reported a net loss of $1.9 million, or $0.11 per share, on revenues of $0.1 million, compared with a net loss of $1.7 million, or $0.10 per share, on revenues of $0.1 million, for the same period in the prior year.

7 Aug 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Lexicon Pharmaceuticals, Inc., today reported financial results for the second quarter ended June 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

7 Aug 2015

Hill-Rom Holdings' revenue increases 19% to $475 million in third quarter 2015

Hill-Rom Holdings, Inc. announced financial results for its third quarter ended June 30, 2015 and updated its 2015 financial outlook. Adjusted earnings per diluted share of $0.62 increased 5 percent from $0.59 in the prior year, while reported earnings per diluted share of $0.33 decreased from $0.45. Adjustments to reported earnings are detailed in the reconciliation schedules provided.

7 Aug 2015

Curo Consulting receive Queen’s Award for Enterprise

Tech Company Curo Consulting have received the highest accolade given to British business. In July, Her Majesty’s representative, the Lord Lieutenant of Buckinghamshire, Sir Henry Aubrey-Fletcher visited Curo Consulting’s offices in Marlow to present the award in person. The team were also invited to attend a reception at Buckingham palace.

6 Aug 2015

Neovasc's second quarter revenues drop 18%

Neovasc Inc. today announced financial results for the quarter ended June 30, 2015.

6 Aug 2015

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Antiva Biosciences, Inc. (formerly Hera Therapeutics), a biopharmaceutical company developing antiviral therapeutics, today announced that it has raised $16 million in a Series B financing, its first institutional round.

6 Aug 2015

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, is pleased to announce that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds.

6 Aug 2015

BD reports adjusted revenues of $3.133 billion for third fiscal quarter 2015

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly adjusted revenues of $3.133 billion for the third fiscal quarter ended June 30, 2015, an increase of 45.2 percent over the prior-year period as reported, or 55.6 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted revenues grew 2.4 percent. As reported, revenues were $3.120 billion.

From BD (Becton, Dickinson and Company) 6 Aug 2015

WI Harper Group announces investment in Cold Genesys

WI Harper Group, a leading US & China, cross-border early growth and expansion stage venture capital firm, today announced an investment in Cold Genesys Inc, a clinical-stage privately-held biotech company developing oncolytic immunotherapies for cancer.

6 Aug 2015

Business / Finance

Sinovac Biotech releases results of 2015 Annual General Meeting of Shareholders held in Beijing, PRC

Endra photoacoustic CT preclinical imaging technology to be brought to Australia by AXT

VolitionRx reports net loss of $1.9 million for second quarter 2015

Deerfield provides $20 million financing to Editas Medicine

BioScrip revenue increases 6.2% to $262.4 million in second quarter 2015

Impax sells U.S. rights to Daraprim brand for $55 million to Turing Pharmaceuticals

Intrexon, Synthetic Biologics form ECC to develop and commercialize novel biotherapeutics for phenylketonuria

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Turing Pharmaceuticals completes $90 million Series A financing

Mallinckrodt subsidiary to acquire Therakos for $1.325 billion

GenVec reports net loss of $1.9 million for second quarter 2015

Lexicon Pharmaceuticals' revenues decrease to $0.4 million in second quarter 2015

Hill-Rom Holdings' revenue increases 19% to $475 million in third quarter 2015

Curo Consulting receive Queen’s Award for Enterprise

Neovasc's second quarter revenues drop 18%

Antiva raises $16 million in Series B financing to advance antiviral compound through Phase 1 clinical trials

Heptares, AstraZeneca sign licensing agreement to develop and commercialise immuno-oncology treatments

BD reports adjusted revenues of $3.133 billion for third fiscal quarter 2015

WI Harper Group announces investment in Cold Genesys

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News